Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive assessment of HCV RNA kinetics as an early predictor of lack of sustained virologic response in chronic hepatitis C treated with pegylated interferon and ribavirin
2009-012459-96Phase 4Active
- Sponsor
- Calleja Panero
- Start
- Mar 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of peginterferon alfa-2b, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Calleja Panero. Primary endpoint: Early viral response at cohort time points before week 12. Started Mar 2010; status: active.
02
Drugs
peginterferon alfa-2bpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-012459-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012459-96.